Renascience Inc. (JP:4889)
:4889
Top Page
Renascience Inc.
(4889)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥1,610.00
▲(12.12% Upside)
Action:ReiteratedDate:03/24/26
The score is primarily supported by a strengthened FY2025 profitability profile and a conservative, debt-free balance sheet. Offsetting this are persistent operating/free cash flow deficits and a technically weak price trend with the stock below major moving averages, while valuation signals are limited by a negative P/E and отсутствing dividend yield.
Positive Factors
Debt-free balance sheet
A zero-debt, equity-rich balance sheet gives the company durable financial flexibility: it lowers insolvency risk, enables funding R&D or partnerships without immediate refinancing pressure, and supports multi-quarter investment choices even if cash flow remains weak.
Negative Factors
Persistent cash burn
Negative operating and free cash flows despite reported net income indicate earnings may not be converting into sustainable cash. Continued cash burn creates ongoing funding needs, risks dilution or constraints on investment, and undermines long-term self-funded growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt, equity-rich balance sheet gives the company durable financial flexibility: it lowers insolvency risk, enables funding R&D or partnerships without immediate refinancing pressure, and supports multi-quarter investment choices even if cash flow remains weak.
Read all positive factors
Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥22.24B
Dividend YieldN/A
Average Volume (3M)312.67K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-32.68%
EPS GrowthN/A
CountryJP
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.21
Shares Outstanding13,776,900
10 Day Avg. Volume205,420
30 Day Avg. Volume312,670
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)7.74
Price to Sales (P/S)100.40
P/FCF Ratio-75.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Renascience Inc. Business Overview & Revenue Model
Company Description
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignan...
Renascience Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69M | 132.69M | 194.16M | 100.55M | 139.33M | 209.80M |
| Gross Profit | 98.37M | 128.95M | 165.64M | 100.30M | 77.60M | 179.82M |
| EBITDA | 94.34M | 143.82M | -250.50M | -332.49M | -244.65M | -89.39M |
| Net Income | 62.45M | 113.43M | -258.33M | -335.80M | -254.29M | -100.05M |
Balance Sheet | ||||||
| Total Assets | 1.73B | 1.87B | 2.09B | 2.27B | 2.44B | 1.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.67B | 1.80B | 2.03B | 2.21B | 2.39B | 1.03B |
| Total Debt | 0.00 | 0.00 | 356.10M | 309.60M | 199.23M | 475.65M |
| Total Liabilities | 79.72M | 151.21M | 482.11M | 409.76M | 237.17M | 505.10M |
| Stockholders Equity | 1.65B | 1.72B | 1.61B | 1.87B | 2.20B | 561.53M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -177.14M | -232.10M | -286.87M | -231.66M | -90.27M |
| Operating Cash Flow | 0.00 | -176.34M | -230.52M | -284.64M | -230.49M | -89.25M |
| Investing Cash Flow | 0.00 | 382.15M | -1.57M | 232.00K | -296.00K | -1.72M |
| Financing Cash Flow | 0.00 | -52.18M | 46.50M | 110.37M | 1.59B | 135.65M |
Renascience Inc. Technical Analysis
Negative
1436.00
Price Trends
1737.58
Negative
1730.45
Negative
1983.17
Negative
Market Momentum
-43.02
Positive
41.59
Neutral
25.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Negative. The current price of 1436 is below the 20-day moving average (MA) of 1824.15, below the 50-day MA of 1737.58, and below the 200-day MA of 1983.17, indicating a bearish trend. The MACD of -43.02 indicates Positive momentum. The RSI at 41.59 is Neutral, neither overbought nor oversold. The STOCH value of 25.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4889.
Renascience Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.36B | 120.78 | ― | ― | 1.24% | -33.41% | |
52 Neutral | ¥22.24B | -67.88 | ― | ― | -32.68% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.41B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥50.09B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.20B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥18.99B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4889
Renascience Inc.
1,614.00
596.00
58.55%
JP:4593
Healios KK
371.00
149.00
67.12%
JP:4599
StemRIM Inc.
303.00
32.00
11.81%
JP:4978
ReproCELL Inc.
172.00
43.00
33.33%
JP:7774
Japan Tissue Engineering Co., Ltd.
601.00
196.00
48.40%
JP:7776
CellSeed Inc.
288.00
-179.00
-38.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.